Antibody-based therapeutics show great promise, especially against cancer. Pipeline 2 explores the emerging field of next-generation antibody therapeutics, including Antibody-Drug Conjugates, Bispecific Antibody Therapeutics and engineering antibodies that fight cancer. The weeklong Antibody Therapeutics pipeline reveals R&D strategies, clinical results and efficacy data for these promising molecules.

Conferences Include:

January 18-19

Next-Generation Cancer Immunotherapies

January 19-20

Antibody-Drug Conjugates

January 21-22

Bispecific Antibody Therapeutics